Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05795595 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors | PHASE1 | COMPLETED | 19 | — | — | Mar 13, 2023 | Sep 18, 2025 | Nov 26, 2025 | 7 | United States |
Defined as dose-limiting toxicities
ORR based on Independent Review Committee (IRC) assessment, defined as the proportion of subjects who have achieved a best overall response of CR or PR according to appropriate response evaluation criteria for each disease histology
| Arm | Type | Description |
|---|---|---|
| CTX131 | EXPERIMENTAL | Administered by IV infusion following lymphodepleting chemotherapy. |
| Name | Type | Description |
|---|---|---|
| CTX131 | BIOLOGICAL | CTX131 (CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components) |
Key Inclusion Criteria: 1. Age ≥18 years. 2. Unresectable or metastatic, relapsed/refractory, clear cell renal cell carcinoma, cervical carcinoma, pancreatic adenocarcinoma, esophageal carcinoma, and malignant pleural mesothelioma. 3. Eastern Cooperative Oncology Group performance status 0 or 1. 4....